Bortezomib Plus Melphalan-Induced Cardiomyopathy Presenting as Sinus Tachycardia and Systolic Heart Failure

Parth J Sampat; Sana Riaz; Fidel Martinez; Dana Aiello

doi:10.7759/cureus.9488

Bortezomib Plus Melphalan-Induced Cardiomyopathy Presenting as Sinus Tachycardia and Systolic Heart Failure

Cureus. 2020 Jul 31;12(7):e9488. doi: 10.7759/cureus.9488.

Authors

Parth J Sampat¹, Sana Riaz¹, Fidel Martinez², Dana Aiello²

Affiliations

¹ Internal Medicine, State University of New York Upstate Medical University, Syracuse, USA.
² Cardiology, State University of New York Upstate Medical University, Syracuse, USA.

Abstract

Chemotherapy-induced cardiotoxicity is a known condition, however, bortezomib and melphalan do not typically cause cardiotoxicity. With the rise in the use of newer chemotherapeutic agents, it is important to identify and understand the cardiac implications of chemotherapeutic agents. We present a case of a 70-year-old female with no known significant cardiac history presenting with partially reversible cardiomyopathy with initial presentation only being as sinus tachycardia.

Keywords: bortezomib; cardiomyopathy; cardiotoxicity; melphalan; sinus tachycardia; systolic heart failure.

Publication types

Case Reports